The group's principal activity is to develop, promote and distribute ozone-generating equipment and related products for medical applications. As on 31-Dec-2003, the group's activity is in the development stage. The group is seeking regulatory approval for the drug called medizone(R), which is a precise mixture of ozone and oxygen. The drug can be used as a therapeutic drug in humans to inactivate certain viruses and to treat certain viral diseases including aids-related virus, hepatitis b, hepatitis c, epstein-barr, herpes, cytomegalovirus and to decontaminate blood and blood products. The group owns two patents for process and equipment that includes ozone decontamination of blood and blood products, approaches for the control generation and administration of ozone and external application of ozone/oxygen for external applications.
